Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Income from Continuing Operations (2020 - 2024)

Immuneering has reported Income from Continuing Operations over the past 5 years, most recently at 18142915.0 for Q4 2024.

  • Quarterly results put Income from Continuing Operations at 18142915.0 for Q4 2024, down 16.69% from a year ago — trailing twelve months through Dec 2024 was 61478101.0 (down 12.17% YoY), and the annual figure for FY2025 was 56336563.0, up 8.36%.
  • Income from Continuing Operations for Q4 2024 was 18142915.0 at Immuneering, down from 14726676.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for IMRX hit a ceiling of 3604162.0 in Q2 2020 and a floor of 18142915.0 in Q4 2024.
  • Median Income from Continuing Operations over the past 5 years was 12793156.0 (2022), compared with a mean of 11293144.74.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 121.62% in 2021 and later dropped 0.81% in 2023.
  • Immuneering's Income from Continuing Operations stood at 5835937.0 in 2020, then plummeted by 88.02% to 10972870.0 in 2021, then dropped by 22.75% to 13468839.0 in 2022, then fell by 15.44% to 15547844.0 in 2023, then decreased by 16.69% to 18142915.0 in 2024.
  • The last three reported values for Income from Continuing Operations were 18142915.0 (Q4 2024), 14726676.0 (Q3 2024), and 14087644.0 (Q2 2024) per Business Quant data.